Navigation Links
Tapestry Initiates Phase 2 Trial of TPI 287 for the Treatment of Advanced Pancreatic Cancer
Date:10/3/2007

atient recruitment, formulation and manufacturing difficulties, delays in finalizing and receiving approval of protocols, negotiations with regulatory agencies, or other factors; that human clinical trials may show that TPI 287 is unsafe and/or ineffective in treating cancer in humans. General implementation risks associated with development of TPI 287 include those that we are blocked or limited in the development of TPI 287 because of the intellectual property rights of third parties; that we are limited in our ability to obtain, maintain and enforce our own intellectual property; that development of TPI 287 is delayed or terminated because the costs of further development exceed its value; and that the Company's resources will be insufficient to continue development. Additional risks, uncertainties and other factors are identified under the captions "Risk Factors" and "Special Note Regarding Forward-Looking Statements" in the Company's reports filed from time to time with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q for the periods ended March 28, 2007, and June 27, 2007. The Company cautions investors not to place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update publicly or revise any forward-looking statements, whether as a result of new or additional information, future events or otherwise.

Tapestry Pharmaceuticals, Inc.

Gordon Link

Senior Vice President, Chief Financial Officer

303-516-8500

glink@tapestrypharma.com

Investor:

Stern Investor Relations, Inc.

212-362-1200

lilian@sternir.com

Media:

Andrea tenBroek

Schwartz Communications

781-684-0770

tapestry@schwartz-pr.com


'/>"/>
SOURCE Tapestry Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Tapestry Pharmaceuticals to Present Data on TPI 287 at the 2007 AACR Annual Meeting
2. Malvern initiates European user group meetings for chemical imaging
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... , Sept. 15, 2014 /PRNewswire-iReach/ -- CaPtivate ... biotechnology company developing calcium phosphate (CaP)-based nanoparticle drug ... company has entered a License Agreement with Immunotope ... company developing immunotherapy products for the treatment and ... Under the terms of the agreement, Immunotope ...
(Date:9/15/2014)... PDL BioPharma, Inc. (PDL) (NASDAQ: ... September 12, 2014, regular quarterly dividend payment of $0.15 per ... of September 5, 2014, the record date. ... portfolio of patents and royalty assets, consisting primarily of ... agreements with various biotechnology and pharmaceutical companies. PDL pioneered ...
(Date:9/15/2014)... Sept. 15, 2014 Research and Markets ... (CAS 103-90-2) Market Research Report 2014" report to ... Market Research Report 2014 presents comprehensive data on paracetamol ... , Asia , North ... includes paracetamol (acetaminophen) description, covers its application areas and ...
Breaking Medicine Technology:CaPtivate Pharmaceuticals Enters License Agreement With Immunotope 2CaPtivate Pharmaceuticals Enters License Agreement With Immunotope 3PDL BioPharma Completes Regular Quarterly Dividend Payment 2Paracetamol (Acetaminophen) (CAS 103-90-2) Market Research Report 2014 2Paracetamol (Acetaminophen) (CAS 103-90-2) Market Research Report 2014 3
... HealthWarehouse.com, Inc. (ticker: HEWA) a leading VIPPS-accredited, ... President and CEO, will present at RetailInvestorConferences.com. Company ... virtual conference.DATE: , May 5, 2011TIME: ... the red "register/ watch event now" button.This will ...
... 2, 2011 Stereotaxis, Inc. (NASDAQ: STXS ... ended March 31, 2011.  First quarter results included continued ... the Company,s Odyssey™ systems and growth in recurring revenue. ... Epoch™ platform, which enhances the efficiency and versatility of ...
Cached Medicine Technology:HealthWarehouse.com, Inc. to Present Live at RetailInvestorConferences.com on May 5th 2Stereotaxis Reports First Quarter 2011 Financial Results 2Stereotaxis Reports First Quarter 2011 Financial Results 3Stereotaxis Reports First Quarter 2011 Financial Results 4Stereotaxis Reports First Quarter 2011 Financial Results 5Stereotaxis Reports First Quarter 2011 Financial Results 6Stereotaxis Reports First Quarter 2011 Financial Results 7
(Date:9/16/2014)... Dr. Eric Millstein of Beverly Hills is ... a specialty website devoted to the diagnosis and treatment ... lover and athlete, Dr. Millstein focuses on offering patients ... to maintain active, healthy lifestyles. , “We’re very excited ... specifically to ACL injuries and treatment,” says ...
(Date:9/16/2014)... 16, 2014 Lambda Solutions, a leader in ... is excited to welcome Stewart Rogers on board ... Executive at Lambda Solutions comments, “Product leadership will take Lambda ... to do so. Learning and talent management is at a ... help clinical learning and talent development in the past ten ...
(Date:9/16/2014)... Texas (PRWEB) September 16, 2014 Online ... be offering $0 shipping on all kettlebell purchases in ... easy for customers to get started with this effective ... the Crossfit movement. The online store carries a variety ... and free weekly workouts guides. , “We’ve ...
(Date:9/16/2014)... justthoughtyoushouldknow.org , popular current events, ... new site today. The new site is better ... information easier to find, ingest, and share. , ... easy-to-read pages the information that we believe any ... retired college professor and founder of the site. ...
(Date:9/16/2014)... 2014 Dakota Software , ... (EHS) and Sustainability management software, today announced that ... versatile software platform, MobileWorkflows, at their Annual Users ... MobileWorkflows allow for on-the-go access to Dakota’s enterprise-level ... Responsive Web Design, MobileWorkflows feature a streamlined user ...
Breaking Medicine News(10 mins):Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 2Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 3Health News:Stewart Rogers Joins Lambda Solutions as Director of Product Management 2Health News:Stewart Rogers Joins Lambda Solutions as Director of Product Management 3Health News:Join the Kettlebell Movement - Kettlebell Kings Announces $0 Shipping on all Orders 2Health News:JustThoughtYouShouldKnow.org Debuts New Website 2Health News:Mobile EHS Compliance Tools the Focus of Dakota Software’s 2014 Users Conference 2
... In the report titled Millennium Ecosystem Assessment, scientists have said ... having a detrimental effect to human health and may cause ... malaria and cholera are threatening to cause a major outbreak ... beneficial factors of the eco system are being used in ...
... published in American Journal of Public Health, researchers had been ... causes of asthma in children by interventions due to health ... children in the age group of 4 to 12 yrs ... period of one year during which community health workers used ...
... US and Canadian scientists, consuming food with high glycemic index ... ,The study, which had spanned 16.6 years and observed ... that the risk is much significant for women who are ... often found in foods that have simple carbohydrates and sugars ...
... a data comprising of 5461 girls between 11 to 15 ... these girls more prone to stress fractures. ,The study ... physical activity, which often lasts for 16 or more hours ... of having a stress fracture than the girls doing physical ...
... market watchdog Food and Drug Administration had announced a series ... class of non-steroidal anti-inflammatory drugs that are sold with or ... of the drug Bextra (valdecoxib) from Pfizer, Inc. ... FDA had reports that the overall risk associated with the ...
... have completed the second phase of testing of the ... of cervical cancers and 90% of genital warts. ... for 36 months and regularly had gynecological examination, cervicovaginal ... serum antibodies to HPV. , ,The results showed ...
Cached Medicine News:
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: